ClinicalTrials.gg
CompletedNCT07909902Updated Nov 2, 2026

A Clinical Trial of Local Infiltration With Injection CZ1S for Postoperative Analgesia After Hemorrhoidectomy

A Phase 3 interventional study of CZ1S for injection and ropivacaine in Hemorrhoids Second Degree, Hemorrhoids Third Degree and Analgesia, sponsored by Zhejiang Cuize Pharmaceutical Technology Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by Zhejiang Cuize Pharmaceutical Technology Co., Ltd. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 4 months after the study started (first participant enrolled May 2025, registered Oct 2026).
Updated Nov 2, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
243
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This is a multicenter, randomized, double-blind, active-controlled and placebo-controlled phase III clinical trial, aiming to evaluate the efficacy and safety of intravenous injection of CZ1S for local infiltration after hemorrhoidectomy in terms of pain relief.

Read the detailed description

This study used the pain intensity score of the Numerical Rating Scale (NRS) as the indicator, and compared it with the saline solution. The efficacy of the injectable CZ1S for local infiltration in postoperative anal canal resection for pain relief was evaluated. The safety of the injectable CZ1S, the hydrochloric acid ropivacaine injection, and the saline solution for local infiltration in postoperative anal canal resection was also assessed and compared.

02

Conditions studied

  • Hemorrhoids Second Degree
  • Hemorrhoids Third Degree
  • Analgesia

Keywords

  • Postoperative analgesia for hemorrhoids surgery
03

In context

Lead sponsor

Zhejiang Cuize Pharmaceutical Technology Co., Ltd. is the lead sponsor of 2 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The subjects can understand the procedures and methods of this clinical trial, have given full , and voluntarily participate and sign the informed consent form.
  2. Male or female individuals aged 18 to 65 years old; with a (BMI) within the range of [18.0 - 30.0] kg/m2 (including the critical value).
  3. Those who plan to undergo external dissection and internal ligation under general anesthesia.
  4. (ASA) classification levels I-II.
  5. The subjects must agree to take effective measures from after signing the informed consent to 30 days after medication administration.

Exclusion criteria

Exclusion Criteria:

  1. The subjects had pain unrelated to hemorrhoid diseases, and the researchers judged that it might confuse the postoperative assessors.
  2. Those who planned to undergo surgeries in other parts at the same time.
  3. Those with any of the following clinical severe disease histories or current severe diseases: ① respiratory system diseases ② neurological and mental disorders ③ circulatory system diseases ④ blood system diseases ⑤ tumors ⑥ digestive system diseases ⑥ having other diseases that might significantly affect the efficacy evaluation or in vivo metabolism of the test drug.
  4. Those who have undergone hemorrhoid resection surgery before.
  5. Those with fecal incontinence, perianal abscess, etc.
  6. Those with a history of constipation and the researchers judged that it might affect the postoperative pain assessment.
  7. Those who had vomiting during the screening period or had a history of severe, postoperative nausea and vomiting.
  8. Those who have obvious to the prescribed medication.
  9. Those with laboratory test results during the screening period.
  10. Those with prolonged interval during the screening period: male ≥ 450 ms, female ≥ 470 ms.
  11. Those who are allergic to any component of the test drug, general anesthesia medication, rescue analgesic medication, antiemetic medication, or have a history of specific reactions.
  12. Those who used or were expected to use opioids, NSAIDs, sedative anesthetics, local anesthetics, , anti-epileptic drugs, anti-anxiety drugs, anti-depressants, drugs with analgesic effect of traditional Chinese medicine/herbs, class III anti-arrhythmic drugs, strong CYP1A2 inhibitors, CYP1A2 highly sensitive substrates, strong inhibitors, CYP3A4 highly sensitive substrates, strong CYP3A4 inducers within the first 5 half-lives of screening.
  13. Those who frequently drink alcohol within 3 months before screening (90 days), that is, those who consume more than 14 units of alcohol per week (1 unit = 360 mL of beer or 45 mL of 40% alcohol liquor or 150 mL of wine).
  14. Those who participated in clinical trials of drugs or devices within 3 months before screening and received treatment with the test drug or device.
  15. Those who have a history of drug abuse or drug use within the past 1 year.
  16. Those whose blood or urine pregnancy test is positive during the screening period, or are in lactation.
  17. Those who, in the researcher's opinion, cannot evaluate the efficacy or are unlikely to complete the trial.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
243 participants (actual)

Study arms

  • Active comparator
    Ropivacaine hydrochloride

    75mg (30mL)

    Drug: ropivacaine

  • Placebo comparator
    normal saline

    30 mL

    Drug: Normal Saline (0.9% NaCl)

  • Experimental
    CZ1S for injection

    600mg (30mL)

    Drug: CZ1S for injection

Interventions

  • DrugCZ1S for injection

    intervention group

  • positive control

  • DrugNormal Saline (0.9% NaCl)

    blank control

06

What researchers measure

Primary outcomes

  1. The NRS was used to assess the resting pain intensity score within 72 hours after administration. The area under the curve (AUC0-72h) of the resting pain intensity score for the test drug and the placebo control were compared.

    Time frame: 72 hours

  2. The NRS was used to assess the resting pain intensity score within 48 hours after administration. The area under the curve (AUC0-48h) of the resting pain intensity score for the test drug and the hydrochloride ropivacaine injection were compared.

    Time frame: 48 hours

Secondary outcomes

  1. Compare the area under the time-curves of resting pain intensity scores for the test drug and the placebo control group from 0 to 24 hours and from 0 to 48 hours after administration.

    Time frame: from 0 to 24 hours and from 0 to 48 hours after administration.

  2. Compare the area under the time-curves (AUC) of the resting pain intensity scores for the test drug and the hydrochloric acid ropivacaine injection from 0 to 24 hours and from 0 to 72 hours after administration.

    Time frame: from 0 to 24 hours and from 0 to 72 hours after administration.

07

Study locations

1 site
  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
    Wuhan, Hubei 430022, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2025 to primary completion in Oct 2025, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 19, 2026
First posted
Nov 2, 2026
StartActual
May 21, 2025
Primary completionActual
Oct 11, 2025
CompletionActual
Oct 11, 2025
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07909902
Lead sponsor
Zhejiang Cuize Pharmaceutical Technology Co., Ltd.
Responsible party
Sponsor
First posted
Nov 2, 2026
Start date
May 21, 2025
Primary completion
Oct 11, 2025
Completion
Oct 11, 2025
Last update
Nov 2, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion